A dibenzylamine compound represented by the formula (1) ##STR00001## wherein R.sup.1 and R.sup.2 are each a C.sub.1-6 alkyl group optionally substituted by halogen atoms and the like; R.sup.3, R.sup.4 and R.sup.5 are each a hydrogen atom, a halogen atom and the like, or R.sup.3 and R.sup.4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is --N(R.sup.7) (R.sup.8) and the like; ring B is an aryl group or a heterocyclic residue; R.sup.6 is a hydrogen atom, a halogen atom, a nitro group, a C.sub.1-6 alkyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.